Ubicom Holdings. Inc. · TSE:3937
Ubicom — FY2026 Q2 Earnings Presentation
39 slides from Ubicom's earnings presentation, Nov 12, 2026
Slide 1: FY2026 Q2 Financial Results Materials
Ubicom Holdings, Inc. (Standard Market of TSE: 3937) FY2026 Q2 Financial Results Materials November 12, 2026 (Note) FY2026 (fiscal year ending March 31, 2027)
Slide 2: Table of Contents
Table of Contents 01 Highlights of Consolidated Financial Results for FY2026 Q2 P.3 02 Overview of Consolidated Financial Results (P/L) for FY2026 Q2 P.4 03 Medical Business P.5 04 AI Technology Strategy Business P.14 05 Dividend Policy P.23 06 Business Forecast & Performance Trends P.25 07 Appendix
Slide 3: Highlights of Consolidated Financial Results for FY2026 Q2
Highlights of Consolidated Financial Results for FY2026 Q2 Company performance: In FY2026 Q2, sales, operating income, ordinary income, and interim net income all exceeded the same period of the previous year, setting new second-quarter records. Progress toward the full-year plan remained solid.
Slide 4: Overview of Consolidated Financial Results (P/L) for FY2026 Q2
Overview of Consolidated Financial Results (P/L) for FY2026 Q2 Sales increased by 18.8% year on year and operating income by 19.9%, reflecting steady growth. Progress toward the full-year business forecast remained solid: 47.9% for sales, 52.8% for operating income, 54.6% for ordinary income, and 54
Slide 5: Medical Business
Medical Business 5
Slide 6: Medical Business: Overview by Segment for FY2026 Q2
Medical Business: Overview by Segment for FY2026 Q2 (Business Performance) As a healthcare platform provider, the Company continues to steadily build its recurring revenue base through its Mighty series and Insurance Knowledge Platform, while expanding its revenue scale through M&A. As a result, bot
Slide 7: Mighty Series User Base Trend
AI×Subscription Model: Mighty Series User Base Trend Healthcare DX investment accelerated following physician work-style reforms and medical fee revisions in April 2024, driving steady growth in new users alongside existing customer migration. Hospitals (Unit: facilities) 22,912 23,453 Clinics 21,94
Slide 8: Improving Profitability Through Group-Wide Cross-Selling and Stronger Direct Sales
Improving Profitability Through Group-Wide Cross-Selling and Stronger Direct Sales Radianceware’s earnings contribution, combined with greater use of the three Group companies’ customer bases, products, and sales capabilities, is strengthening the Group’s earnings base. Continued M&A will accelerate
Slide 9: Strategy to Maximize Radianceware's Profitability
Strategy to Maximize Radianceware’s Profitability Radianceware’s Growth Opportunities Radianceware’s Key Challenges Strong Demand for Healthcare IT Systems Driven Tripling headcount through recruitment and reallocation to address by Medical DX Vision 2030 *1. strong demand and strengthen consultativ
Slide 10: AI x High-Margin Recurring Core Solutions: the Mighty Series
AI × High-Margin Recurring Core Solutions: the “Mighty” Series Cross-selling the Mighty series to deliver revenue growth and cost savings for medical institutions. Leveraging these improvements to strengthen sales proposals for EMR and related systems. Driving Solutions Through the Mighty series Key
Slide 11: Insurance Knowledge Platform: Driving DX in the Insurance Industry
Insurance Knowledge Platform: Driving DX in the Insurance Industry A business support platform streamlining benefit claims assessment for life insurers. A Win-Win-Win Solution Driving Insurance Medical Data × Proprietary AI Recurring Revenue Growth Through Industry DX Through Medical Data × AI Advant
Slide 12: Long-Term Strategy: M&A Strategy
Long-Term Strategy: M&A Strategy (Nationwide Distributor Acquisitions) From 2025 through 2030, the Company will pursue M&A to maximize the profitability of the Medical Business. By building its own nationwide direct sales network and direct customer relationships, the Group aims to capture more reve
Slide 13: Scenarios for Medium to Long-Term Growth in the Medical Business
Scenarios for Medium to Long-Term Growth in the Medical Business Achieving sustainable mid- to long-term growth through both organic growth in stable recurring revenues and inorganic growth through M&A. Positioning M&A as a strategic investment to expand business scale and enhance future earnings ca
Slide 14: AI Technology Strategy Business
AI Technology Strategy Business 14
Slide 15: AI Technology Strategy Business: Overview by Segment for FY2026 Q2
AI Technology Strategy Business: Overview by Segment for FY2026 Q2 (Business Performance) Profitability improved, driven by revenue growth at the Philippine subsidiary, cost structure reforms, and a stronger AI-driven development framework. Both sales and operating income increased year on year, wit
Slide 16: Philippine Subsidiary: Evolving to a Global AI Profit Center
Philippine Subsidiary: Evolving from a “Development Base” to a “Global AI Profit Center” The Philippine subsidiary achieved record high sales and operating income. Under the Go Global strategy, the expansion of direct-contract projects, including AI-related projects with leading U.S. healthcare
Slide 17: Overview of the Business Model Transformation to an AI-Driven Development Framework
Overview of the Business Model Transformation to an AI-Driven Development Framework AI Technology Strategy Business-Growth Strategy Overview, FY2026 Onward The Company is advancing its transition from a man-month-based model dependent on “headcount × time” to an AI-driven development framework lev
Slide 18: Business Model Transformation through AI-Driven Development
Business Model Transformation through AI-Driven Development Initiative Content Phase Progress 【FY2025 Q3 – Q4】 • Analyzed watsonx*1 assets using the Company’s technical and English-language Develop AI-native engineers / Expand AI Building the AI Completed capabilities to build a delivery framework p
Slide 19: AI Projects: Strengthening the Strategic Partnership with Kobelco Systems
AI Projects: Horizontal Deployment — Strengthening the Strategic Partnership with Kobelco Systems The Company is expanding the horizontal deployment of its AI-driven development technologies and knowledge, strengthening its strategic partnership with Kobelco Systems to accelerate business growth and
Slide 20: Market Opportunities: Growing Demand for Modernization
Market Size of the Modernization Field and the Company’s Competitive Advantages Going forward, the Company will leverage “IBM Bob” and “ALSEA” to modernize existing systems and accelerate the expansion of its AI-driven development business. The Company’s Competitive Advantages As IBM's strategic par
Slide 21: Overview of AI Use Cases (by Industry)
Overview of AI Use Cases (by Industry) AI is utilized across areas including the upstream phase (requirements definition), and cross-industry AI adoption is expanding. With the establishment of the AI-driven development framework complete, the Company is accelerating the creation of high value-added
Slide 22: Target Domains for Building an AI-Driven Development Framework
Target Domains for Building an AI-Driven Development Framework The generative AI market is expected to expand over the medium to long term both in Japan and worldwide, with growing demand for AI utilization across industrial domains such as finance, manufacturing, healthcare, and social infrastructu
Slide 23: Dividend Policy
Dividend Policy 23
Slide 24: A dividend policy enabling shareholders to directly benefit from growth
A dividend policy enabling shareholders to directly benefit from growth 【Dividend Policy】 ① Although FY2025 results fell short of the initial forecast due to temporary impacts from growth investments and business portfolio optimization, the Medical Business continued to strengthen its earnings found
Slide 25: Business Forecast & Performance Trends
Business Forecast & Performance Trends 25
Slide 26: Business Forecast and Financial Performance Trend
Business Forecast and Financial Performance Trend [Business Forecast Assumptions] • For FY2026 forecast, we expect further expansion of the revenue base in the Medical Business and contributions from newly acquired subsidiaries through M&A. • The forecast incorporates higher depreciation expenses re
Slide 27: Business Forecast and Financial Performance Trend: Key Strategic Initiatives
Business Forecast and Financial Performance Trend 【Key Strategic Initiatives】 ① Continuous execution of M&A strategy The Company will continuously promote M&A to expand its revenue base and accelerate the accumulation of recurring income. Early realization of synergies will be achieved through post-
Slide 28: Appendix
Appendix 28
Slide 29: Our Business Model: Resolving Social Issues in Japan
Our Business Model: A Model for Resolving Social Issues in Japan, A Developed Country Facing Challenges 01 Medical Business 02 AI Technology Strategy Business Reforming the workstyle of Against the backdrop of an medical professionals anticipated shortage of 3.26 million Improving the profitability
Slide 30: Medical Business: The Tailwind Created by Social Issues and Policy Measures
Medical Business: The Tailwind Created by Social Issues and Policy Measures (Market Environment) Increasing deficits of medical institutions and social security spending cuts: three growth opportunities arising from structural challenges Increasing deficits in The coverage rate of EMR is Business fi
Slide 31: Medical Business: Impact of M&A Strategy Execution (KPI Changes)
Medical Business: Impact of M&A Strategy Execution (KPI Changes) Over the five years from 2025 to 2030, we will execute 8 to 10 M&A deals with the aim of increasing the Group's direct sales ratio. <Factors contributing to LTV *1 improvement> Content Measurement Details Increase of ①Inclusion of agen
Slide 32: Medical Business: Revenue Recognition Methods (Billing Methods)
Medical Business: Revenue Recognition Methods (Billing Methods) License revenue for the Mighty series is recognized on a straight-line basis. With the increase in contract numbers, sales steadily accumulate on a monthly basis, achieving revenue stabilization. Furthermore, the AI × subscription model
Slide 33: M&A Strategy Phase 2: Maximizing Medical Business Profitability
M&A Strategy Phase 2: Maximizing Medical Business Profitability Radianceware Financial Performance Trend Over the Quantitative Evaluation and Investment Past Three Years Decision for This M&A (Unit: million yen) Sales 2 consecutive years of ① Comparison with Target Payback Period revenue and profit
Slide 34: Launch of New Product MightyChecker Cloud X
Launch of New Product “MightyChecker® Cloud X” N e x t - g e n e r a t i o n c l o u d - b a s e d me d i ca l c l a i ms i n s p e c t i o n s o f t w a re Launch of New Product “MightyChecker® Cloud X” (April 2026) Features of MightyChecker® Cloud X Targets Improved Operational Efficiency Migratio
Slide 35: Promotion of Group Businesses Based on Social Significance
Promotion of Group Businesses Based on Social Significance Provision of solutions that are beneficial to three key areas: pressing need for workstyle reforms for medical doctors, improvement Growing demand due to the reassessment of in management of medical institutions, and offshore development par
Slide 36: ESG: For sustainable growth of business, society, and client companies
ESG:For sustainable growth of business, society, and client companies Goals Concrete Activities Related SDGs ・To make the electric power consumed E ・To reduce CO2 emissions at the head office 100% derived from renewable energy ・Global partnership ・Investment in equipment of subsidiaries in the Phili
Slide 37: Corporate Profile
Corporate Profile ■Corporate name: Ubicom Holdings, Inc. (Standard Market of TSE: 3937) ■Strategic markets: healthcare, finance, public services, automobiles, manufacturing, robotics, real estate, energy, etc. ■Business description: AI Technology Strategy Business In order to solve the problem of sh
Slide 38: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements The materials and information provided in this announcement include forward-looking statements based on our current estimates and expectations at this point of time. Such forward-looking statements are subject to various risks and uncertaintie
Slide 39: Holdings, Inc.
Holdings, Inc. = fe) Q Q =) 39